age1

age1 investment thesis

About Portfolio Team Library Early backer of breakthrough, founder-led longevity companies All age1 The Longevity Fund Precision therapeutics for genetic forms of neurodegeneration EXITED: IPO First-in-class foundational checkpoint immunotherapies NASDAQ: ALXO Discovering new medicines with ultra-throughput biochemistry and machine learning Next-generation interventions to cure neurodegeneration and delay brain aging Targeting pathogenic cells to treat aging and chronic diseases Turning stem cells into human eggs to reimagine family planning EXITED: IPO Regenerative and gene therapies to restore hearing and balance NASDAQ: DBTX Activation of the endogenous immune system for eliminating pathogenic cells AI-led drug discovery engine translating conserved pathways of disease resistance across

age1 team (1)

Partners and principals at age1:

• Satvik Dasariraju — sweet spot $2M

age1 portfolio companies

Companies listed on age1's public materials include: About, Portfolio, Team, Library, Next generation of induced proximity medicines, Healthspan and lifespan extension for dogs, Platform for therapeutics targeting mTORC1, Therapeutics to heal the blood-brain barrier, Stealth, Multiplex-editing therapies to target age-related disease, Vision, Careers, FAQ, Founders, Talent, Twitter, LinkedIn, apply now.

Is age1 a fit for your round?

Upload your pitch deck and see whether anyone at age1 appears in your top matches.